The need for and timing of a booster dose in subjects previously vaccinated with Menveo is to be defined based on national recommendations. Menveo may be given as a booster dose in subjects who have previously received primary vaccination with Menveo, other conjugated meningococcal vaccine or meningococcal unconjugated polysaccharide vaccine. Department of Health & Human Services,Meningococcal conjugate or MenACWY vaccines (Menactra,Serogroup B meningococcal or MenB vaccines (Bexsero,All preteens and teens at 11 to 12 years old with a booster dose at 16 years old,Children and adults at increased risk for meningococcal disease,People 10 years or older at increased risk for meningococcal disease,Meningitis=infection of the lining of the brain and spinal cord,Meningococcemia= meningococcal bloodstream infection,Meningococcal polysaccharide vaccine=MPSV4.The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.You will be subject to the destination website's privacy policy when you follow the link.CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. MENVEO is approved for use in persons aged 2 months thr ough 55 years. Following a positive recommendation from the,In November 2013, in response to an outbreak of B-serotype meningitis on the campus of.The occurrence of serogroup X has been reported in North America, Europe, Australia, and West Africa.Common side effects include pain and redness around the site of injection (up to 50% of recipients). Administration route: Intramuscular injection. MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Tell your doctor if you are breast-feeding a baby.Menveo vaccine should not be given to anyone younger than 2 months or older than 65 years of age.Menveo is given as an injection (shot) into a muscle. MENVEO is approved for use in … You may report vaccine side effects to the US Department of Health and Human Services at 1 800 822 7967.Before receiving Menveo, tell your doctor about all other vaccines you have recently received, especially:a diphtheria, tetanus, and pertussis vaccine (such as Daptacel); or.Also tell the doctor if you have recently received drugs or treatments that can weaken the immune system, including:an oral, nasal, inhaled, or injectable steroid medicine;If you are using any of these medications, you may not be able to receive the vaccine, or may need to wait until the other treatments are finished.This list is not complete. However, if you are pregnant, your doctor should determine whether you need this vaccine.If you are pregnant, your name may be listed on a pregnancy registry. Print. Available for Android and iOS devices.Select one or more newsletters to continue.We comply with the HONcode standard for trustworthy health information -.Antibiotics & Drinking Alcohol - Is it Safe. (1) -----DOSAGE AND ADMINISTRATION----- • For intramuscular injection only (0.5 mL). ��!�&�M�O��qZ�̙�2��Ҕ�����f0�f��^�5�i�Aw&W��=i����at���� ������5�@ 24�,�,;�B6��������b L " � @2����(� d0�@��q88��$�,888�$X. Teens and young adults (16 through 23 year olds) also may get a serogroup B meningococcal vaccine.
A booster dose should be given at age 16 for continued protection when teens are at highest risk of meningococcal disease.Your booster schedule may be different from these guidelines. A small proportion of people develop a severe allergic reaction.Quadrivalent (Serogroups A, C, W-135, and Y).Finne J et al. However, like any medicine, Menveo can cause side effects but the risk of serious side effects is extremely low.You may feel faint after receiving Menveo. Menveo is approved for use in persons aged 2 months through 55 years. Menveo is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.